Original Items
Validation of a data collection instrument on side effects of the CoronaVac vaccine from the teaching-learning process of the Research Methodology subject
Elianne Rodríguez-Larraburu- Ivis Piovet-Hernández
- Kety Bernardes-Carballo
Published 2023-12-29
Keywords
- data collection,
- secondary effects,
- vaccination,
- aged,
- coronavirus infections
How to Cite
Validation of a data collection instrument on side effects of the CoronaVac vaccine from the teaching-learning process of the Research Methodology subject. (2023). Identidad Bolivariana, 7(3), 202-219. https://doi.org/10.37611/IB7ol3202-219
Abstract
The subject of Research Methodology, taught at the Bolivarian Institute of Technology, faces challenges in the design and validation of documentary measurement tools. The objective of the current study was to validate a data collection instrument on the side effects of the CoronaVac vaccine in older adults, integrated into the teaching-learning process of the aforementioned subject. An instrument was designed and subjected to content and construct validation through the expert judgment of healthcare professionals using the Delphi Method. Subsequently, a pilot test was conducted. In this way, it was concluded that the designed instrument demonstrated both content and construct validity.
Downloads
Download data is not yet available.
References
- Binay, U., Karakecili, F., Binali, E., Barkay, O., Gul, O., & Mertoglu, C. (2021). Level of SARS-CoV-2 IgG antibodies after two doses CoronaVac vaccine: Primarily report. Research Square. https://doi.org/10.21203/rs.3.rs-388073/v2
- Cabezas, C. (2020). Pandemia de la COVID-19: Tormentas y retos. Revista Peruana de Medicina Experimental y Salud Pública, 37(4), 603–604. https://doi.org/10.17843/rpmesp.2020.374.6866
- Karamese, M., & Tutuncu, E. E. (2022). The effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on antibody response in participants aged 65 years and older. Journal of Medical Virology, 94, 173–177. https://doi.org/10.1002/JMV.27289
- Riad, A., Pokorná, A., Attia, S., Klugarová, J., Koščík, M., & Klugar, M. (2021). Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic. Journal of Clinical Medicine, 10(7), 1428. https://doi.org/10.3390/jcm10071428
- Santander Rigollet, S., González Caro, C., Avendaño Vigueras, M., Rivas Iglesias, M., Rojas González, C., & Saavedra Gajardo, C. (2021). Ficha vacuna contra SARS-COV-2 vacuna Coronavac laboratorio Sinovac Life Science®.
- Sauré, D., Basso, L. J., Basso, L. J., Sauré, D., Pablo Torres, J., Zuniga, M., & Santelices, E. (2022). Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study. Articles Lancet Infect Dis, 22, 56–63. https://doi.org/10.1016/S1473-3099(21)00479-5
- Useche, M. C., Artigas, W., Queipo, B., & Perozo, É. (2019). Técnicas e instrumentos de recolección de datos cuali-cuantitativos. Universidad de La Guajira.
- Wan, E. Y. F., Wang, Y., Chui, C. S. L., Mok, A. H. Y., Xu, W., Yan, V. K. C., Lai, F. T. T., Li, X., Wong, C. K. H., Chan, E. W. Y., Lau, K. K., Cowling, B. J., Hung, I. F. N., & Wong, I. C. K. (2022). Safety of an inactivated, whole-virion COVID-19 vaccine (CoronaVac) in people aged 60 years or older in Hong Kong: a modified self-controlled case series. The Lancet Healthy Longevity, 3(7), e491–e500. https://doi.org/10.1016/S2666-7568(22)00125-8
- Wong, C. K. H., Lau, K. T. K., Xiong, X., Au, I. C. H., Lai, F. T. T., Wan, E. Y. F., Chui, C. S. L., Li, X., Chan, E. W. Y., Gao, L., Cheng, F. W. T., Tang, S. C. W., & Wong, I. C. K. (2022). Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study. PLOS Medicine, 19(6), e1004018. https://doi.org/10.1371/JOURNAL.PMED.1004018
- Wu, Z., Hu, Y., Xu, M., Chen, Z., Yang, W., Jiang, Z., Li, M., Jin, H., Cui, G., Chen, P., Wang, L., Zhao, G., Ding, Y., Zhao, Y., & Yin, W. (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases, 21(6), 803–812. https://doi.org/10.1016/S1473-3099(20)30987-7
- Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., Han, W., Chen, Z., Tang, R., Yin, W., Chen, X., Hu, Y., Liu, X., Jiang, C., Li, J., Yang, M., Song, Y., Wang, X., Gao, Q., & Zhu, F. (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases, 21(2), 181–192. https://doi.org/10.1016/S1473-3099(20)30843-4